For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative costs | 488,385 | |||
| Total operating expenses | 488,385 | |||
| Loss from operations | -488,385 | |||
| Interest earned on cash and investments held in trust account | 4,933,800 | |||
| Gain on extinguishment of over-allotment option liability | 553,748 | |||
| Provision for credit losses | 812,113 | |||
| Total other income | 4,675,435 | |||
| Net income (loss) | 4,187,050 | |||
| Basic EPS | 0.16 | |||
| Diluted EPS | 0.15 | |||
| Basic Average Shares | 13,287,671 | |||
| Diluted Average Shares | 13,287,671 | |||
Drugs Made In America Acquisition II Corp. (DMIIR)
Drugs Made In America Acquisition II Corp. (DMIIR)